A successful collaboration between academia, biotech and pharma led to discovery of erdafitinib, a selective FGFR inhibitor recently approved by the FDA

Christopher W. Murray; David R. Newell; Patrick Angibaud

doi:10.1039/c9md90044f

A successful collaboration between academia, biotech and pharma led to discovery of erdafitinib, a selective FGFR inhibitor recently approved by the FDA

Authors: Christopher W. Murray, David R. Newell, Patrick Angibaud - MedChemComm 2019 cited by 79

The winners of the Malcolm Campbell Memorial Prize for 2019 discuss the discovery of erdafitinib.

A successful collaboration between academia, biotech and pharma led to discovery of erdafitinib, a selective FGFR inhibitor recently approved by the FDA | Litlas